Ruijie Geng

Ruijie Geng

Auto-generated profile, based on publicly available information

Ruijie Geng

Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 200030 Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2023
Verified
Conference Paper
Open access
CLChen Liang
Chen Liang
YIYasha Iravantchi
Yasha Iravantchi
TKThomas Krolikowski
Thomas Krolikowski
RGRuijie Geng
Ruijie Geng
ASAlanson P. Sample
Alanson P. Sample
AGAnhong Guo
Anhong Guo
Touchscreen devices, designed with an assumed range of user abilities and interaction patterns, often present challenges for individuals with diverse abilities to operate independently. Prior efforts to improve accessibility through tools or algorithms necessitated alterations to touchscreen hardware or software, making them inapplicable for the large number of existing legacy devices. In this paper, we introduce BrushLens, a hardware interaction proxy that performs physical interactions on behalf of users while allowing them to continue utilizing accessible interfaces, such as screenreaders and assistive touch on smartphones, for interface exploration and command input. BrushLens maintains an interface model for accurate target localization and utilizes exchangeable actuators for physical actuation across a variety of device types, effectively reducing user workload and minimizing the risk of mistouch. Our evaluations reveal that BrushLens lowers the mistouch rate and empowers visually and motor impaired users to interact with otherwise inaccessible physical touchscreens more effectively.

22 December 2025 in ALPHA PSYCHIATRY
Verified
Journal Article
Open access
PDF file
YWYingyi Wang
Yingyi Wang
HWHaisu Wu
Haisu Wu
RGRuijie Geng
Ruijie Geng
CWChongze Wang
Chongze Wang
QLQinyu Lv
Qinyu Lv
ZYZhenghui Yi
Zhenghui Yi
Objective: To explore the molecular mechanisms underlying clozapine-induced metabolic syndrome (MetS) in schizophrenia patients, providing scientific evidence for clinicians to prevent and manage metabolic syndrome during the treatment of psychiatric disorders. Methods: Ten schizophrenia patients with MetS and ten matched controls were recruited from Shanghai Mental Health Center according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia and the 2016 Chinese Adult Dyslipidemia Prevention and Treatment Guidelines for MetS. Peripheral blood RNA sequencing was performed to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network were used to pinpoint hub genes. Mendelian randomization (MR) was conducted to validate causal relationship between serum brain-derived neurotrophic factor (BDNF) levels and MetS components. Results: A total of 1019 DEGs were identified, grouped into eight mRNA modules through WGCNA. Key hub genes included RP11-611O2.6, acid phosphatase-like 2 (ACPL2), T cell receptor alpha variable 12-2 (TRAV12-2), matrix metallopeptidase 8 (MMP8), piggyBac transposable element derived 4 pseudogene 1 (PGBD4P1), transmembrane protein 261 (TMEM261), and BDNF, with BDNF and MMP8 further validated by PPI network analysis. MR analysis confirmed a causal association between BDNF levels and MetS risk, reinforcing its role in metabolic dysregulation. Gene Ontology (GO) annotation and pathway enrichment analysis highlighted immune response, morphological changes, and metabolic processes as key biological processes, with pathways such as biological oxidation and defensins significantly enriched. Conclusion: Significant differences in gene expression are observed between schizophrenia patients with and without MetS. Individual variability in clozapine-induced MetS may be linked to DEGs.